



## HOOKIPA Pharma to Present at Upcoming Investor Conferences in September

August 29, 2019

NEW YORK and VIENNA, Austria, Aug. 29, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will present and host one-on-one meetings at the following investor conferences in September:

- Wells Fargo Healthcare Conference 2019 in Boston, on Wednesday, September 4, 2019 at 4:10 p.m. ET
- 26th Annual NewsMakers in the Biotech Industry in New York, on Friday, September 6, 2019 at 9:40 a.m. ET
- Bank of America Merrill Lynch Global Healthcare Conference 2019 in London, on Thursday, September 12, 2019

A live audio webcast of the presentation held at the Wells Fargo Healthcare Conference will be available within the Investors & Media section of HOOKIPA's website at <https://ir.hookipapharma.com/events>. An archived replay will be accessible for 30 days following the event.

### About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system.

HOOKIPA's proprietary arenavirus-based technologies, VaxWave<sup>®\*</sup>, a replication-deficient viral vector, and TheraT<sup>®\*</sup>, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration while maintaining an immune response. TheraT<sup>®</sup> has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA's "off-the-shelf" viral vectors target dendritic cells in vivo to activate the immune system.

HOOKIPA's VaxWave<sup>®</sup>-based prophylactic cytomegalovirus vaccine candidate is currently in a Phase 2 clinical trial in patients awaiting kidney transplantation from living cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.

TheraT<sup>®</sup> and VaxWave<sup>®</sup> are not approved anywhere globally and their safety and efficacy have not been established.

Find out more about HOOKIPA online at [www.hookipapharma.com](http://www.hookipapharma.com).

\*Registered in Europe; Pending in the US.

For further information, please contact:

#### Media

Nina Waibel  
Senior Director - Communications  
[Nina.Waibel@HookipaPharma.com](mailto:Nina.Waibel@HookipaPharma.com)

#### Investors

Matt Beck  
Executive Director - Investor Relations  
[Matthew.Beck@HookipaPharma.com](mailto:Matthew.Beck@HookipaPharma.com)

#### Media enquiries

Sue Charles/ Ashley Tapp  
Instinctif Partners  
[Hookipa@Instinctif.com](mailto:Hookipa@Instinctif.com)  
+44 (0)20 7457 2020